Johnson & Johnson (JNJ) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 243,466 shares of the company’s stock after selling 4,005 shares during the period. Johnson & Johnson accounts for 0.8% of Oppenheimer & Co. Inc.’s investment portfolio, making the stock its 13th biggest holding. Oppenheimer & Co. Inc.’s holdings in Johnson & Johnson were worth $31,200,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of JNJ. Enterprise Financial Services Corp boosted its holdings in Johnson & Johnson by 2.4% in the 4th quarter. Enterprise Financial Services Corp now owns 15,075 shares of the company’s stock valued at $2,106,000 after purchasing an additional 358 shares during the period. Welch Investments LLC boosted its holdings in Johnson & Johnson by 1.0% in the 4th quarter. Welch Investments LLC now owns 35,981 shares of the company’s stock valued at $5,027,000 after purchasing an additional 373 shares during the period. YHB Investment Advisors Inc. boosted its holdings in Johnson & Johnson by 0.5% in the 4th quarter. YHB Investment Advisors Inc. now owns 76,534 shares of the company’s stock valued at $10,693,000 after purchasing an additional 381 shares during the period. Franklin Parlapiano Turner & Welch LLC boosted its holdings in Johnson & Johnson by 1.0% in the 4th quarter. Franklin Parlapiano Turner & Welch LLC now owns 38,387 shares of the company’s stock valued at $5,363,000 after purchasing an additional 382 shares during the period. Finally, Regent Investment Management LLC boosted its holdings in Johnson & Johnson by 0.8% in the 4th quarter. Regent Investment Management LLC now owns 47,171 shares of the company’s stock valued at $6,591,000 after purchasing an additional 385 shares during the period. Institutional investors own 65.96% of the company’s stock.

Johnson & Johnson opened at $122.84 on Monday, according to Marketbeat Ratings. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. The firm has a market cap of $329.57 billion, a PE ratio of 16.83, a P/E/G ratio of 1.88 and a beta of 0.73.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The company had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. During the same period in the previous year, the firm posted $1.83 EPS. The firm’s revenue was up 12.6% compared to the same quarter last year. equities analysts expect that Johnson & Johnson will post 8.13 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th were paid a $0.90 dividend. The ex-dividend date of this dividend was Friday, May 25th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 annualized dividend and a yield of 2.93%. Johnson & Johnson’s payout ratio is currently 49.32%.

Several brokerages have commented on JNJ. Stifel Nicolaus cut their price target on shares of Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating for the company in a report on Wednesday, April 18th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 price target for the company in a report on Wednesday, April 11th. Jefferies Financial Group set a $161.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Friday, March 23rd. Citigroup cut their price target on shares of Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating for the company in a report on Monday, April 23rd. Finally, Deutsche Bank reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 18th. Six research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $142.23.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply